Shares of Sanofi (NYSE:SNY) fell 0.3% on Friday . The company traded as low as $40.82 and last traded at $40.85, with a volume of 617,239 shares traded. The stock had previously closed at $40.99.

A number of research firms have recently weighed in on SNY. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, June 6th. JPMorgan Chase & Co. restated a “sell” rating on shares of Sanofi in a research note on Monday, March 14th. Citigroup Inc. restated a “neutral” rating on shares of Sanofi in a research note on Wednesday, April 27th. HSBC lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, May 3rd. Finally, Bank of America Corp. restated a “buy” rating and issued a $58.00 target price on shares of Sanofi in a research note on Tuesday, May 3rd. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and a consensus price target of $49.67.

The firm’s 50-day moving average price is $40.28 and its 200-day moving average price is $40.77. The company has a market capitalization of $105.27 billion and a price-to-earnings ratio of 22.18.

A number of institutional investors have bought and sold shares of the stock. Morgan Stanley raised its position in Sanofi by 34.9% in the fourth quarter. Morgan Stanley now owns 3,660,972 shares of the company’s stock valued at $156,140,000 after buying an additional 946,483 shares during the period. Seminole Management Co. Inc. acquired a new position in Sanofi during the fourth quarter valued at approximately $26,208,000. Tekla Capital Management LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $13,008,000. Freestone Capital Holdings LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $1,672,000. Finally, First Trust Advisors LP raised its position in Sanofi by 25.9% in the fourth quarter. First Trust Advisors LP now owns 163,637 shares of the company’s stock valued at $6,979,000 after buying an additional 33,688 shares during the period.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.